## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tb-500-sciatica`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tb-500-sciatica/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-sciatica/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500-sciatica/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tb-500-sciatica/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500-sciatica/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tb-500-sciatica/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tb-500-sciatica` v2 · content_hash `60b9fe93ec330c31…` · thread_head genesis · 26 DIVs
- **thesis (c1):** TB-500 shows cell migration and anti-inflammatory effects in preclinical models including limited intervertebral disc data.
  - c2 [human/active] No human interventional studies exist for TB-500 in spine or sciatica applications.
  - c4 [human/active] ARA-290 improved neuropathic symptoms and small nerve fiber density in human sarcoidosis and diabetic neuropathy trials.
  - c5 [human/active] Small human pilots report short-term tolerability for BPC-157 with no adverse events in tested biomarkers.
  - c3 [preclinical/active] BPC-157 improved axonal regeneration in a 2010 rat transected sciatic nerve study.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tb-500-sciatica/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tb-500-sciatica/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tb-500-sciatica`
- **title:** TB-500 for Sciatica: Evidence-Graded Review of Repair Pathways
- **url:** https://miscsubjects.com/a/tb-500-sciatica
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:18.403Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have Sciatica

Sciatica involves nerve pain along the sciatic nerve, commonly from disc herniation or spinal stenosis that compresses a nerve root. The nerve signals ongoing damage or compression. Suppressing pain signals does not address the underlying compression or tissue breakdown. Breakdown outpaces repair when repair cells fail to reach the site, inflammation stalls, blood supply remains poor, collagen organizes poorly, and nerve fibers lose density or function. Each layer contributes to persistent symptoms.

## Why TB-500 might help you

1. You have Sciatica — breakdown is outpacing repair.
2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.
5. This article centers TB-500; see other sections for BPC-157 and ARA-290 — different layers, same condition.

## Why BPC-157 might help you

1. You have Sciatica — breakdown is outpacing repair.
2. What keeps failing: Poor blood supply at injury, weak collagen organization, slow tissue turnover.
3. What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.
4. Therefore for you: If that layer is part of your problem, BPC-157 is discussed because it targets repair (structure / tissue) — not because it masks pain.

## Why ARA-290 might help you

1. You have Sciatica — breakdown is outpacing repair.
2. What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.
3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.

## How these fit together

Each compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.
- TB-500 → inflammation clearance / repair-cell migration
- BPC-157 → structure / tissue
- ARA-290 → nerve / innervation

Primary focus of this slug: TB-500. Others are in scope because the same condition breaks down on multiple layers.

## What the evidence actually shows

TB-500 (thymosin beta-4 fragment) shows cell migration and anti-inflammatory effects in preclinical models, including limited data on intervertebral disc cells. No human interventional studies exist for spine or sciatica applications. Human data are limited to Phase 1 safety studies in healthy volunteers showing good tolerability.

BPC-157 improved axonal regeneration and functional recovery in a 2010 rat study of transected sciatic nerve. Small human studies (retrospective knee pain, pilot interstitial cystitis, IV safety in 2 adults) report symptom improvement or tolerability but lack controls or sciatica-specific designs.

ARA-290 improved neuropathic symptoms and small nerve fiber density in human trials for sarcoidosis-associated and diabetic small fiber neuropathy. No direct sciatica trials.

## What scientists say

Reviews note the evidence base for TB-500 and related peptides is largely preclinical with sparse direct musculoskeletal human data. Rat nerve injury work for BPC-157 demonstrates faster regeneration but remains animal-only. ARA-290 has published human neuropathy trials supporting nerve repair signaling.

## What people say on Reddit

Anecdotal reports describe pain relief with BPC-157 or stacks including TB-500 for back and leg pain, but these are uncontrolled self-reports without verified diagnoses or outcomes.

## What people say on X

Limited public posts echo user experiences of reduced nerve pain after peptide use, consistent with Reddit patterns but equally anecdotal and unverified.

## What we do not know

No randomized controlled human trials exist for any of these compounds specifically in sciatica. Long-term safety, optimal combinations, and effects on actual disc or nerve compression remain untested in people. Weight loss effects on spinal load are established mechanically but not linked to these peptides in studies.

## Safety and limits

Preclinical safety data exist for the compounds studied; small human pilots report short-term tolerability. Unregulated sources carry contamination or dosing risks. No compound replaces medical evaluation or addresses mechanical compression directly.

## Claims (5)

- **c5** [human w=0.8] Small human pilots report short-term tolerability for BPC-157 with no adverse events in tested biomarkers.
  - who_claims: grok/grok-4.3
  - slot: limitations
  - sources: s18
- **c4** [human w=0.8] ARA-290 improved neuropathic symptoms and small nerve fiber density in human sarcoidosis and diabetic neuropathy trials.
  - who_claims: grok/grok-4.3
  - sources: s19, s21
- **c3** [preclinical w=0.5] BPC-157 improved axonal regeneration in a 2010 rat transected sciatic nerve study.
  - who_claims: grok/grok-4.3
  - sources: s9
- **c2** [human w=0.8] No human interventional studies exist for TB-500 in spine or sciatica applications.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c1** [preclinical w=0.5] TB-500 shows cell migration and anti-inflammatory effects in preclinical models including limited intervertebral disc data.
  - who_claims: grok/grok-4.3
  - sources: s3

## Voxel graph (5 atoms · 11 edges)
- full graph: https://miscsubjects.com/api/articles/tb-500-sciatica/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `92b76ebcaad18180`

### s3 · pubmed · http_403
- title: Thymosin Beta-4 and TB-500 in Tissue Healing ...
- url: https://www.mdpi.com/2076-3417/16/12/6202
- summary: Systematic mapping of 80 studies showing sparse human musculoskeletal data for TB-500/TB4.
- quote: No human interventional studies of administered TB4 or TB-500 were identified in tendon, ligament, muscle, bone, cartilage, adipose/fat graft, or spine/intervertebral disc categories
- claim_ids: c1, c2
- hash: `d0636167eadced33`

### s9 · pubmed · ok
- title: Peptide therapy with pentadecapeptide BPC 157 in ...
- url: https://pubmed.ncbi.nlm.nih.gov/19903499/
- summary: 2010 rat study on transected sciatic nerve showing improved regeneration with BPC-157.
- quote: BPC 157 markedly improved rat sciatic nerve healing.
- claim_ids: c3
- hash: `1b7a2d1cb0909995`

### s18 · pubmed · ok
- title: Safety of Intravenous Infusion of BPC157 in Humans
- url: https://pubmed.ncbi.nlm.nih.gov/40131143/
- summary: Pilot human safety study of BPC-157 IV.
- quote: Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated.
- claim_ids: c5
- hash: `92b76ebcaad18180`

### s19 · pubmed · ok
- title: Safety and Efficacy of ARA 290 in Sarcoidosis Patients ...
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC3563705/
- summary: Human trial of ARA-290 in sarcoidosis SFN patients.
- quote: We studied the safety and efficacy of ARA 290 to reduce symptoms of small fiber neuropathy (SFN) in patients with sarcoidosis.
- claim_ids: c4
- hash: `87d25b3fe87154e9`

### s21 · pubmed · ok
- title: Targeting the innate repair receptor to treat neuropathy
- url: https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx
- summary: Review summarizing human ARA-290 neuropathy trials.
- quote: In humans, ARA290 has been evaluated in patients with small fiber neuropathy associated with sarcoidosis or type 2 diabetes (T2D) mellitus.
- claim_ids: c4
- hash: `cce79aea7829ef48`

## Provenance (2 model passes)
- chain valid: yes · head: `95e0d4128fc845f9`

- write · grok/grok-4.3 · 2026-06-29T23:31 · hash `61a2a9259410`
- voxel_divide · owner · 2026-07-17T02:42 · hash `95e0d4128fc8`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tb-500-sciatica/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tb-500-sciatica/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tb-500-sciatica","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tb-500-sciatica|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tb-500-sciatica|tier|assertion`
- **iMessage ask:** `tb-500-sciatica|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tb-500-sciatica`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-sciatica/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500-sciatica/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*